@FierceMedDev: Intersect ENT pulls in $30M Series D for sinusitis-implant sales push. More | Follow @FierceMedDev
@MarkHFierce: Another successful post-marketing test will help fuel adoption of CardioDx's coronary artery disease Dx. News | Follow @MarkHFierce
@DamianFierce: Despite the uptick in scrutiny, Indian clinical trial deaths were about the same in 2012 as in 2011. Story | Follow @DamianFierce
> Ocular Therapeutix submitted an FDA premarket approval application for Resure Sealant, an ophthalmic device designed to seal clear corneal incisions after lens implantation surgery. Release
> NxStage Medical won a CE mark in Europe for its OneSite single needle device for use with dialysis patients. Item
> Peru's regulators published draft regulations designed to revamp the country's device classification system. Item
> ReShape Medical completed enrollment in a 326 person pivotal trial designed to test its intragastric balloon, which it bills as among the first non-surgical weight loss devices developed for the U.S. market. Release
> Stratasys, based in Israel and Minnesota, is developing a 3-D printer that can, in part, produce customized medical devices. Story
> The blog InventorSpot highlights some of the more unusual Japanese medical devices now in the market. Item
Biotech News
@FierceBiotech: In case you missed it last week: Fierce's Top 10 Biotech Techies - 2013. Special Report | Follow @FierceBiotech
@JohnCFierce: Royalty offer of $6.5B for Elan is smart. Investors can choose cash or Kelly Martin? No brainer. Just sweeten and stir. News | Follow @JohnCFierce
@RyanMFierce: Genentech opens mobile app playbook for tablet fans. Story | Follow @RyanMFierce
> Merck KGaA reports another R&D setback with PhIII brain cancer failure. News
> Dynavax regroups after FDA turns thumbs down on hep B vaccine Heplisav. Story
Pharma News
@FiercePharma: Reckitt Benckiser's heroin addiction drug Suboxone gets 2 generic rivals, despite co's attempt to block them. More | Follow @FiercePharma
@EricPFierce: Qualicaps, which Mitsubishi is buying, is investing $26 million to expand a plant in North Carolina. Article | Follow @EricPFierce
@AlisonBFierce: The FDA rejected Dynavax's Heplisav, an adult hepatitis B vaccine, causing shares to slide as much as 38 percent. News | Follow @AlisonBFierce
> Pfizer eyes more Chinese partners to speed growth. Article
> Ranbaxy back in gear for generic Lipitor production. News
> Allergan CEO nabs 51% pay hike with $9.4M one-time bonus. Story
> Affymax, Takeda pull Omontys after 3 deaths. Report
CRO News
> Chinese CRO ShangPharma one step closer to going private. Item
> Moody's says Quintiles is worth $4B, but IPO price remains mystery. Story
> Lonza inks $6.9M stem cell supply deal with NIH. News
> After Warnex buy, Biotrial jumps into bioanalytics. More
> Indian clinical trial deaths unchanged from 2011. Report
Biotech IT News
> Genentech opens mobile app playbook for tablet fans. News
> Medidata grabs software deal with Purdue Pharma. Article
> Ex-Merck dreamer Friend sharpens open science nonprofit with 'competition' edge. Story
> Boost in sales, customers pumps up Medidata's 2012 revenue. More